Even with the strength in medical device stocks this year, IHI sports a P/E ratio of 25.76, which is below that of 28.8 sported by the iShares U.S. Pharmaceuticals ETF (NYSEArca: IHE) and far below the P/E of 44.1 found on the iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), according to iShares data. IHI also has a three-year standard deviation that is 250 basis points below that of IBB’s.
iShares U.S. Medical Devices ETF
ETF Trends editorial team contribute to this post. Tom Lydon’s clients own shares of Apple and Amazon.